
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell is a promising MedTech company with a Buy rating as its Ceribell System, designed for rapid EEG monitoring, has gained significant commercial traction and is supported by strong financials. Additionally, the company has a solid pipeline, including new indications like delirium and ischemic stroke detection, which could further drive growth. Despite potential risks related to tariffs and competition, CeriBell's unique offerings and commercial strategy make it a strong investment opportunity.
Bears say
CeriBell is facing growing competition from companies like Zeto Inc. and may struggle to maintain market share. Their 2026 growth drivers are highly dependent on expanding within existing and new accounts and may not materialize as expected. Risks such as geopolitical tensions and R&D efforts may also impact the company's performance and ability to meet investors' expectations.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares